Forkhead Biotherapeutics, Inc.
Weston, MA · Biotech · Private
Oral small-molecule FOXO1 inhibitor that reprograms gut endocrine cells to secrete insulin in response to glucose
forkheadbio.com →- Grants
- $840K
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Converting gut endocrine cells to glucose-responsive insulin-producing cells by selective Foxo1 inhibition to cure insulin-dependent diabetes | $255,412 | |
| Federal grant | Department of Health and Human Services · Phase II · Converting gut endocrine cells to glucose-responsive insulin-producing cells by selective FOXO1 inhibition to cure insulin-dependent diabetes | $584,112 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2674 | ITERION THERAPEUTICS INC. | — | — |
| 2675 | Qu Biologics Inc. | — | $49K |
| 2676 | Sequence46, LLC | — | $48K |
| 2677 | Forkhead Biotherapeutics, Inc. | — | — |
| 2678 | Arcus, Inc. | — | $35K |
| 2679 | Extended Longevity, Inc. | — | $10K |
| 2680 | EIGER GROUP INTERNATIONAL, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Agents For The Treatment Of Diseases By Inhibition Of FOXO1application
- Agents For The Treatment Of Diseases By Inhibition Of FOXO1application
- Selective Foxo Inhibitors For Treatment Of Diabetes And Other Disorders Related To Impaired Pancreatic Functionapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.